SCHEMBL4691876

SCHEMBL4691876

[O]CC1CNCCO1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16106909 1.00
SCHEMBL197402 0.82
SCHEMBL3962185 0.81
SCHEMBL1746181 0.80 SLC6A2 (0.42)
SCHEMBL536771 0.80 SLC6A2 (0.42)
SCHEMBL3429880 0.79 SLC6A2 (0.40)
SCHEMBL14474333 0.77
SCHEMBL20878691 0.77
Iodide SCHEMBL5326404 0.77 SLC6A2 (0.38)
SCHEMBL6690283 0.77 SLC6A2 (0.45)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 138 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116568304-A Dihydrofuranopyridine derivatives as RHO-kinase inhibitors 奇斯药制品公司 2023-08-08 CN claimed
EP-3402791-A1 SUBSTITUTED THIOHYDANTOIN DERIVATIVES AS ANDROGEN RECEPTOR ANTAGONISTS Janssen Pharmaceutica, N.V. (BE) 2018-11-21 EP claimed
CN-108473471-A Substituted thiourocystine derivatives as androgen receptor antagonists 詹森药业有限公司 2018-08-31 CN claimed
US-10000502-B2 Substituted thiohydantoin derivatives as androgen receptor antagonists JANSSEN PHARMACEUTICA NV (BE) 2018-06-19 US claimed
US-20170233401-A1 SUBSTITUTED THIOHYDANTOIN DERIVATIVES AS ANDROGEN RECEPTOR ANTAGONISTS JANSSEN PHARMACEUTICA NV (BE) 2017-08-17 US claimed
WO-2017123542-A1 SUBSTITUTED THIOHYDANTOIN DERIVATIVES AS ANDROGEN RECEPTOR ANTAGONISTS JANSSEN PHARMACEUTICA NV (BE) 2017-07-20 WO claimed
US-20170029409-A1 COMPOSITIONS USEFUL FOR TREATING DISORDERS RELATED TO KIT BLUEPRINT MEDICINES CORPORATION 2017-02-02 US claimed
US-9499522-B2 Compositions useful for treating disorders related to kit BLUEPRINT MEDICINES CORPORATION (US) 2016-11-22 US claimed
EP-2970231-A1 PIPERAZINE DERIVATIVES AND THEIR USE AS KIT MODULATORS Blueprint Medicines Corporation (US) 2016-01-20 EP claimed
US-20140296206-A1 COMPOSITIONS USEFUL FOR TREATING DISORDERS RELATED TO KIT BLUEPRINT MEDICINES CORPORATION (US) 2014-10-02 US claimed
WO-2014160521-A1 PIPERAZINE DERIVATIVES AND THEIR USE AS KIT MODULATORS BLUEPRINT MEDICINES CORPORATION (US) 2014-10-02 WO claimed
US-6846827-B1 Pyrimidine derivatives ASTRAZENECA AB (SE) 2005-01-25 US claimed
EP-1226126-B1 PYRIMIDINE DERIVATIVES ASTRAZENECA AB (SE) 2005-01-05 EP claimed
CN-1378537-A Pyrimidine derivatives ASTRAZENECA AB (SE) 2002-11-06 CN claimed
EP-1226126-A1 PYRIMIDINE DERIVATIVES AstraZeneca AB (SE) 2002-07-31 EP claimed
WO-2001027089-A1 PYRIMIDINE DERIVATIVES ASTRAZENECA AB (SE) 2001-04-19 WO claimed
EP-4370522-A1 ALKYLIDENE DERIVATIVES AS KRAS INHIBITORS Nikang Therapeutics, Inc. (US) 2024-05-22 EP disclosed
CN-117980310-A Alkylene derivatives as KRAS inhibitors 尼坎治疗公司 2024-05-03 CN disclosed
EP-0411912-A2 Coumarin derivatives, their preparation and their use in the treatment of cerebrovascular disorders Sankyo Company Limited (JP) 1991-02-06 EP disclosed
EP-0382185-A2 Carbostyril derivatives OTSUKA PHARMACEUTICAL CO., LTD. (JP) 1990-08-16 EP disclosed